Division of Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Pediatr Blood Cancer. 2018 Jul;65(7):e27072. doi: 10.1002/pbc.27072. Epub 2018 Apr 10.
Splenectomy is considered an effective treatment for immune thrombocytopenia (ITP) with 70-80% response rate. However, its current use is limited in children with ITP. It is unclear if the rates of splenectomy have changed over time. Using a large nationally representative database, we aimed to study the trends of splenectomy in pediatric hospitalizations with ITP, and the factors associated with splenectomy during these encounters.
Using National (Nationwide) Inpatient Sample (NIS), and international classification of diseases (9th revision), clinical modification (ICD-9-CM) codes, we studied pediatric ITP hospitalizations with occurrence of total splenectomy between 2005 and 2014.
Out of 37,844 weighted ITP hospitalizations from 2005 to 2014; total splenectomy was performed in 954 encounters. Splenectomy rate declined over time (3.4% [2005-2006] to 1.6% [2013-2014], P < 0.001) with the younger age (≤5 years) having the most notable decline (0.91% [2005-2006] to 0.14% [2013-2014], P < 0.001). Splenectomy had higher odds of being performed electively than non-electively (odds ratio [OR]: 19.34, 95% confidence interval [CI]: 12.06-31.02, P < 0.001). Encounters with intracranial bleed were associated with the occurrence of splenectomy (OR: 17.87, 95% CI: 5.07-62.97, P < 0.001). Intracranial bleed (P < 0.001), gastrointestinal bleed (P < 0.01), sepsis (P < 0.001), and thrombosis (P < 0.001) were associated with longer length of stay and higher cost of hospitalization.
Overall, splenectomy rates consistently declined over time. Intracranial hemorrhage during hospitalizations with ITP was associated with occurrence of splenectomy. Future studies should continue to reevaluate the rates of splenectomy in pediatric ITP in the presence of various second-line pharmacologic agents.
脾切除术被认为是治疗免疫性血小板减少症(ITP)的有效方法,有效率为 70-80%。然而,目前在儿童 ITP 中的应用受到限制。目前尚不清楚脾切除术的比率是否随时间而变化。本研究使用大型全国代表性数据库,旨在研究儿童 ITP 住院患者脾切除术的趋势,以及这些情况下与脾切除术相关的因素。
使用国家(全国)住院患者样本(NIS)和国际疾病分类(第 9 版),临床修正(ICD-9-CM)编码,我们研究了 2005 年至 2014 年间发生全脾切除术的小儿 ITP 住院患者。
在 2005 年至 2014 年的 37844 例加权 ITP 住院患者中,共有 954 例患者进行了脾切除术。脾切除术的比率随时间下降(3.4%[2005-2006]至 1.6%[2013-2014],P<0.001),其中年龄较小(≤5 岁)的下降最明显(0.91%[2005-2006]至 0.14%[2013-2014],P<0.001)。选择性脾切除术的可能性高于非选择性脾切除术(比值比[OR]:19.34,95%置信区间[CI]:12.06-31.02,P<0.001)。颅内出血的发生与脾切除术的发生有关(OR:17.87,95%CI:5.07-62.97,P<0.001)。颅内出血(P<0.001)、胃肠道出血(P<0.01)、败血症(P<0.001)和血栓形成(P<0.001)与住院时间延长和住院费用增加有关。
总体而言,脾切除术的比率随时间持续下降。ITP 住院期间的颅内出血与脾切除术的发生有关。未来的研究应继续评估各种二线药物治疗儿童 ITP 时脾切除术的比率。